Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis.

[1]  P. Riedell,et al.  Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. , 2022, The Lancet. Oncology.

[2]  A. Evens,et al.  Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis , 2022, Experimental Hematology & Oncology.

[3]  A. Huitema,et al.  Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia , 2021, Blood advances.

[4]  M. Kersten,et al.  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[5]  Snehit Prabhu,et al.  Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy , 2021, Blood advances.

[6]  Hui Gao,et al.  Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia , 2021, Journal of cellular and molecular medicine.

[7]  John E. Mullinax,et al.  Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma. , 2021, Blood.

[8]  A. Kittai,et al.  Comorbidities Predict Inferior Survival in Patients receiving Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma: A Multicenter Analysis. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[10]  R. Gonzalez,et al.  Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel , 2020, Clinical Cancer Research.

[11]  M. Perales,et al.  Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  Matthew J. Frigault,et al.  Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Junnian Zheng,et al.  Coagulation Disorders after CAR T Cell Therapy: Analysis of 100 Patients with R/R Hematologic Malignancies. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  H. Kotani,et al.  Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy , 2019, British journal of haematology.

[15]  A. Huitema,et al.  Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. , 2019, Blood advances.

[16]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[18]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[19]  D. Teachey,et al.  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia , 2017, Critical care medicine.

[20]  R. Bellomo,et al.  Dialysis: Efficacy of tenapanor in hyperphosphataemia , 2017, Nature Reviews Nephrology.

[21]  S. Oudard,et al.  Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management , 2007, Cancer.

[22]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[23]  S. Rodenhuis,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[24]  U. Hofmann,et al.  Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. , 2002, Kidney international.

[25]  D. Budman,et al.  The Pharmacokinetics and Pharmacodynamics of Fludarabine Phosphate in Patients with Renal Impairment: A Prospective Dose Adjustment Study , 2002, Cancer investigation.